Today's Top Gainer
Note:Top Gainer - Nifty 50 More
Dec 02,2019 10:57 AM
He will succeed Mr M.B. Chinappa, current CFO, who will stay within the Biocon Group of Companies and join Biocon Biologics India
Syngene appoints Sibaji Biswas as CFO Dec 02,2019
Syngene International announces change in CFO Dec 02,2019
Syngene International to hold board meeting Oct 05,2019
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Sun Pharmaceuticals Industries Ltd||434.15||39.80||104,083.15||823.16||0.63||3,215.01||98.33|
|Divis Laboratories Ltd||1,829.15||37.68||48,575.44||352.83||0.87||1,403.92||266.77|
|Dr Reddys Laboratories Ltd||2,905.65||19.19||48,278.18||1,365.10||0.69||3,435.30||852.70|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Syngene International Limited is an internationally reputed custom research and manufacturing organisation, which supports R&D programs from lead generation to clinical supplies. The company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited. The company was formed with objectives of providing contract research service to overseas customer in the field of synthetic chemistry, molecular biology and custom synth... More
Dec 13, 2019 02:27 AM
The company’s standalone revenue stood at Rs467.10cr, up 20.48% yoy and 11.59% qoq.